Suven Pharmaceuticals Future Growth
Future criteria checks 5/6
Suven Pharmaceuticals is forecast to grow earnings and revenue by 31.1% and 25.8% per annum respectively while EPS is expected to grow by 36.5% per annum.
Key information
31.1%
Earnings growth rate
36.5%
EPS growth rate
| Pharmaceuticals earnings growth | 18.5% |
| Revenue growth rate | 25.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2026 | 14,701 | 4,410 | N/A | N/A | 2 |
| 3/31/2025 | 11,528 | 3,900 | N/A | N/A | 1 |
| 6/30/2024 | 9,345 | 2,405 | N/A | N/A | N/A |
| 3/31/2024 | 10,514 | 3,003 | 3,067 | 3,585 | N/A |
| 12/31/2023 | 11,678 | 3,709 | N/A | N/A | N/A |
| 9/30/2023 | 13,017 | 4,318 | 3,130 | 4,318 | N/A |
| 6/30/2023 | 13,491 | 4,243 | N/A | N/A | N/A |
| 3/31/2023 | 13,403 | 4,113 | 1,713 | 4,572 | N/A |
| 12/31/2022 | 13,348 | 3,790 | N/A | N/A | N/A |
| 9/30/2022 | 13,726 | 4,313 | 2,522 | 4,787 | N/A |
| 6/30/2022 | 13,952 | 4,563 | N/A | N/A | N/A |
| 3/31/2022 | 13,202 | 4,538 | 2,548 | 3,300 | N/A |
| 12/31/2021 | 12,155 | 4,453 | N/A | N/A | N/A |
| 9/30/2021 | 10,989 | 3,988 | 2,561 | 3,465 | N/A |
| 6/30/2021 | 10,353 | 3,759 | N/A | N/A | N/A |
| 3/31/2021 | 10,097 | 3,623 | 2,717 | 3,825 | N/A |
| 12/31/2020 | 9,353 | 3,534 | N/A | N/A | N/A |
| 9/30/2020 | 8,391 | 2,977 | 2,518 | 3,843 | N/A |
| 6/30/2020 | 8,746 | 3,166 | N/A | N/A | N/A |
| 3/31/2020 | 8,338 | 3,170 | 3,039 | 4,069 | N/A |
| 3/31/2019 | 9,068 | 2,623 | -153 | 1,210 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 543064's forecast earnings growth (31.1% per year) is above the savings rate (6.7%).
Earnings vs Market: 543064's earnings (31.1% per year) are forecast to grow faster than the Indian market (17.9% per year).
High Growth Earnings: 543064's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 543064's revenue (25.8% per year) is forecast to grow faster than the Indian market (10.2% per year).
High Growth Revenue: 543064's revenue (25.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 543064's Return on Equity is forecast to be high in 3 years time